Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
The Lymphoma Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is one of the leading programs of its kind in the world. More than 95 percent of the children we treat at our center for Hodgkin lymphoma and 80 percent of those treated for non-Hodgkin lymphoma are cured.
We treat all types of Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocytic predominant Hodgkin lymphoma. We also treat non-Hodgkin lymphomas, including lymphoblastic lymphoma, Burkitt’s lymphoma, diffuse large B-cell lymphoma and anaplastic large cell lymphoma.
Dana-Farber/Boston Children’s is an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We offer, in one specialized program, the full spectrum of services that are needed for diagnosis, treatment and ongoing care of even the rarest and hard-to-treat conditions.
Hematologists and oncologists, who are both clinicians and active researchers, form the core of our lymphoma treatment team. They are supported by pediatric radiation oncologists, surgeons, oncology nurses and other medical specialists.
We are a founding member of a small national consortium of leading medical centers investigating new treatments for childhood lymphoma, including innovative drug combinations that deliver results with fewer long-term complications. Our physicians also are involved in clinical trials for newly diagnosed patients and investigational drug therapies at the time of relapse.
Learn more about our Lymphoma Program on the Dana-Farber/Boston Children’s website.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”